JOURNAL HOME CME HOME THIS MONTH PAST ISSUES ETOC COLLECTIONS
AUTHORS REVIEWERS EDITORIAL BOARD FEEDBACK RSS HELP
A&A International Anesthesia Research Society
 QUICK SEARCH:   [advanced]


     


Anesth Analg 1987; 66:39-46
© 1987 International Anesthesia Research Society
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nikki, P. H.
Right arrow Articles by Winter, P. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nikki, P. H.
Right arrow Articles by Winter, P. M.

Absence of ß-Adrenergic Receptor Involvement in Cerebrovascular Dilation by Halothane in Monkeys

Pertti H. Nikki, MD, Edwin M. Nemoto, PhD, Achiel L. Bleyaert, MD, Floyd H. Taylor, SCD, and Peter M. Winter, MD

Department of Anesthesiology and Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, and the Department of Anaesthesiology, University Central Hospital of Helsinki, Helsinki, Finland.

Abstract

We determined, in monkeys, whether halothane-induced cerebrovascular dilation is mediated by ß-adrenergic receptors and whether cerebrovascular tone progressively returns to baseline values during prolonged halothane anesthesia. Total cerebral blood flow (CBF), cerebral perfusion pressure, plasma halothane concentration, and arterial blood gas tensions and pH were measured in 14 rhesus monkeys mechanically ventilated with 0.5% (inspired) halothane, 33% O2 and balance N2O. Halothane was increased to 2.0% and the measurements repeated 30 and 60 min later. Then either 0.9% NaCl (controls n = 6) or propranolol (n = 8), 1.0 mg/kg was infused intravenously over 10 min, and the measurements repeated at 70, 90, 120, and 150 min. After 30 min at 2.0% halothane, CBF increased in the controls by 50% (P < 0.05) from 92 ± 8 (Formula ± sd) to 137 ± 39 ml·100 g–1·min–1 and in the propranolol group by 30% (P < 0.05) from 106 ± 33 to 137 ± 28 ml·100 g–1·min–1. After 2.5 hr of 2.0% halothane anesthesia, CBF remained elevated above baseline levels, but by only 28 and 23% in the control and propranolol groups, respectively. Cerebrovascular resistance was identical in both groups (0.55 ± 0.33 vs 0.53 ± 0.13 mm Hg·ml–1·100 g–1·min–1). The results show that there is only a 10–20% return of CBF toward baseline levels after up to 2.5 hr of 2% halothane anesthesia. The results also indicate that halothane-induced cerebrovascular dilation is not mediated by ß-adrenergic receptors.

Key Words: ANESTHETICS, volatile—halothane. • BRAIN—blood flow.







Lippincott, Williams & Wilkins Anesthesia & Analgesia® is published for the International Anesthesia Research Society® by Lippincott Williams & Wilkins with the assistance of Stanford University Libraries' HighWire Press®. Copyright 2006 by the International Anesthesia Research Society. Online ISSN: 1526-7598   Print ISSN: 0003-2999 HighWire Press
Copyright © 1987 by the International Anesthesia Research Society.